• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Anticoagulation, novel agents, and procedures: can we pardon the interruption?

作者信息

Garcia David A, Granger Christopher B

出版信息

Circulation. 2012 Jul 17;126(3):255-7. doi: 10.1161/CIRCULATIONAHA.112.115188. Epub 2012 Jun 14.

DOI:10.1161/CIRCULATIONAHA.112.115188
PMID:22700855
Abstract
摘要

相似文献

1
Anticoagulation, novel agents, and procedures: can we pardon the interruption?抗凝、新型药物与手术：我们能否原谅这种干扰？
Circulation. 2012 Jul 17;126(3):255-7. doi: 10.1161/CIRCULATIONAHA.112.115188. Epub 2012 Jun 14.
2
Letter by David et al regarding article, "Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) Randomized Trial".
Circulation. 2013 Mar 19;127(11):e504. doi: 10.1161/CIRCULATIONAHA.112.133041.
3
Letter by Hjemdahl et al regarding article, "Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial".
Circulation. 2013 Mar 19;127(11):e505. doi: 10.1161/CIRCULATIONAHA.112.135343.
4
Response to letters regarding article, “Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial”.
Circulation. 2013 Mar 19;127(11):e506. doi: 10.1161/circulationaha.112.154732.
5
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.与华法林相比，达比加群的围手术期出血和血栓栓塞事件：来自随机评估长期抗凝治疗（RE-LY）随机试验的结果。
Circulation. 2012 Jul 17;126(3):343-8. doi: 10.1161/CIRCULATIONAHA.111.090464. Epub 2012 Jun 14.
6
The importance of postapproval data for dabigatran.达比加群批准后数据的重要性。
JAMA Intern Med. 2015 Jan;175(1):25. doi: 10.1001/jamainternmed.2014.6265.
7
Complications associated with oral anticoagulation therapy.
Adv Emerg Nurs J. 2013 Oct-Dec;35(4):283-6. doi: 10.1097/TME.0b013e3182a9e9a2.
8
Dabigatran: uncharted waters and potential harms.达比加群：未知领域与潜在危害。
Ann Intern Med. 2012 Jul 3;157(1):66-8. doi: 10.7326/0003-4819-157-1-201207030-00467.
9
Intensity and quality of warfarin anticoagulation in Chinese patients: setting the record straight.中国患者华法林抗凝治疗的强度与质量：澄清事实
Stroke. 2015 Jan;46(1):5-6. doi: 10.1161/STROKEAHA.114.007486. Epub 2014 Nov 18.
10
Dabigatran and postmarketing reports of bleeding.达比加群与上市后出血报告。
N Engl J Med. 2013 Apr 4;368(14):1272-4. doi: 10.1056/NEJMp1302834. Epub 2013 Mar 13.

引用本文的文献

1
The new oral anticoagulants: practical management for patients attending for endoscopic procedures.新型口服抗凝剂：接受内镜检查患者的实际管理
Frontline Gastroenterol. 2013 Jul;4(3):213-218. doi: 10.1136/flgastro-2013-100325. Epub 2013 Apr 11.
2
Clinical diseases with thrombotic risk and their pharmacologycal treatment: how they change the therapeutic attitude in dental treatments.具有血栓形成风险的临床疾病及其药理学治疗：它们如何改变牙科治疗中的治疗态度。
Med Oral Patol Oral Cir Bucal. 2013 Nov 1;18(6):e888-95. doi: 10.4317/medoral.19561.